Lipella Pharmaceuticals Inc. (NASDAQ:LIPO – Get Free Report)’s stock price dropped 14.8% on Tuesday . The stock traded as low as $0.3410 and last traded at $0.3410. Approximately 22,645 shares traded hands during trading, a decline of 96% from the average daily volume of 631,420 shares. The stock had previously closed at $0.40.
Lipella Pharmaceuticals Price Performance
The stock’s 50-day simple moving average is $0.52 and its two-hundred day simple moving average is $1.06. The firm has a market capitalization of $1.58 million, a P/E ratio of -0.08 and a beta of -0.08.
Lipella Pharmaceuticals Company Profile
Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
See Also
- Five stocks we like better than Lipella Pharmaceuticals
- Financial Services Stocks Investing
- Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
- What Are Dividends? Buy the Best Dividend Stocks
- From Science Project to Solvent: WeRide’s 761% Revenue Surge
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Will the S&P 500 Rally in December? These 3 Signals Point to a Big Move Ahead
Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
